At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CLDI CALIDI BIOTHERAPEUTICS INC
Market Closed 08-28 16:00:00 EDT
1.32
+0.02
+1.54%
盘后1.32
+0.000.00%
19:36 EDT
High1.37Low1.28Vol52.01K
Open1.32D1 Closing1.30Amplitude6.92%
Mkt Cap3.41MTradable Cap3.37MTotal Shares2.58M
T/O68.60KT/O Rate2.04%Tradable Shares2.56M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY
Benzinga Earnings  ·  08-14
Calidi Biotherapeutics Q2 EPS $(2.94) Down From $(1.99) YoY
Calidi Biotherapeutics Q2 FY26 Net Loss Narrows 26.32% to $4.2 Million; General and Administrative Expense Drops 48% to $1.6 Million
Reuters  ·  08-14
Calidi Biotherapeutics Q2 FY26 Net Loss Narrows 26.32% to $4.2 Million; General and Administrative Expense Drops 48% to $1.6 Million
Calidi Biotherapeutics - Reports Q2 Net Loss of $4.20 Mln, or $2.94 Per Share
THOMSON REUTERS  ·  08-14
Calidi Biotherapeutics - Reports Q2 Net Loss of $4.20 Mln, or $2.94 Per Share
Press Release: Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Dow Jones  ·  08-14
Press Release: Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Calidi Biotherapeutics Effects 1-for-16 Reverse Stock Split
Reuters  ·  08-01
Calidi Biotherapeutics Effects 1-for-16 Reverse Stock Split
Calidi Biotherapeutics Targets Q1 2027 Clinic Entry for Cld-401 Cancer Program
Reuters  ·  07-27
Calidi Biotherapeutics Targets Q1 2027 Clinic Entry for Cld-401 Cancer Program
Calidi Biotherapeutics Provides Mid-year Corporate Update and Future Key Value Drivers
THOMSON REUTERS  ·  07-21
Calidi Biotherapeutics Provides Mid-year Corporate Update and Future Key Value Drivers
Calidi Biotherapeutics - Reduces G&a Expenses by $1 Mln from Q1 2025 to Q1 2026
THOMSON REUTERS  ·  07-21
Calidi Biotherapeutics - Reduces G&a Expenses by $1 Mln from Q1 2025 to Q1 2026
Calidi Biotherapeutics - Targets First Patient Dosing in Cld-401 Phase I Trial in Q1 2027
THOMSON REUTERS  ·  07-21
Calidi Biotherapeutics - Targets First Patient Dosing in Cld-401 Phase I Trial in Q1 2027
Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split Effective July 31
Reuters  ·  07-21
Calidi Biotherapeutics Announces 1-for-16 Reverse Stock Split Effective July 31
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
THOMSON REUTERS  ·  07-21
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026
Calidi Biotherapeutics Grants VP Finance Inducement Option for 100,000 Shares at $0.15 Exercise Price
Reuters  ·  07-09
Calidi Biotherapeutics Grants VP Finance Inducement Option for 100,000 Shares at $0.15 Exercise Price
Calidi Biotherapeutics Director Corazon “corsee” Sanders Files Initial Beneficial Ownership Statement
Reuters  ·  06-30
Calidi Biotherapeutics Director Corazon “corsee” Sanders Files Initial Beneficial Ownership Statement
Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit
Reuters  ·  06-24
Calidi Biotherapeutics Presents New Preclinical Data on Trop2-targeting Cld-501 at T-cell Engager Summit
Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board
Reuters  ·  06-23
Calidi Biotherapeutics appoints former Genentech, Celgene executive Corsee Sanders to board
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors
THOMSON REUTERS  ·  06-23
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.d., to Board of Directors
Calidi Biotherapeutics shareholders approve reverse stock split authorization
Reuters  ·  06-19
Calidi Biotherapeutics shareholders approve reverse stock split authorization
Calidi receives pre-IND regulatory feedback from FDA for CLD-401
TIPRANKS  ·  06-16
Calidi receives pre-IND regulatory feedback from FDA for CLD-401
Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback
Reuters  ·  06-16
Calidi Biotherapeutics targets early 2027 start for first-in-human CLD-401 trial after FDA pre-IND feedback
Calidi Biotherapeutics Receives Positive Pre-Ind Feedback From US FDA for Cld-401 Indicating Agreement on Its Current Development Strategy as It Advances Towards a First-in-Human Study
THOMSON REUTERS  ·  06-16
Calidi Biotherapeutics Receives Positive Pre-Ind Feedback From US FDA for Cld-401 Indicating Agreement on Its Current Development Strategy as It Advances Towards a First-in-Human Study

Introduction

Company Name.
CALIDI BIOTHERAPEUTICS INC
Affiliated Markets:
AMEX
Listing Date:
--
Main Business:
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.
Issue price:
--